Trent:₹3,256.10+30.96 (+0.96%)
Reliance Industries:₹1,377.50+1.93 (+0.14%)
Adani Ports:₹1,917.00-0.19 (-0.01%)
Tata Consumer:₹1,155.90+11.90 (+1.04%)
Titan Company:₹4,620.00-79.90 (-1.70%)
TCS:₹2,376.20+33.50 (+1.43%)
Trent:₹3,256.10+30.96 (+0.96%)
Reliance Industries:₹1,377.50+1.93 (+0.14%)
Adani Ports:₹1,917.00-0.19 (-0.01%)
Tata Consumer:₹1,155.90+11.90 (+1.04%)
Titan Company:₹4,620.00-79.90 (-1.70%)
TCS:₹2,376.20+33.50 (+1.43%)
Refer & Earn
Arihant Plus App

Arihant Plus App

OneSource Specialty Pharma Ltd

OneSource Speci. | 544292

Market Closed
₹1,609.30
+₹6.41 (+0.40%)
As on 22/11/26, 10:25 AM
Market Cap18,381.12 CR
Current Price₹1,609.3
High / Low₹1,917.8 / 1,057
PE Ratio0
Book Value₹508.7
Dividend Yield0.00%
ROCE0.00%
ROE0.34%
Face Value₹2.00
Current Vol.1,78,590
Average Vol.---
ISININE013P01021
PB Ratio2.89
Debt to Equity0.17
Net Profit Margin-4.5
Operating Margin22.47

ONESOURCE - Share Price Chart

+₹0.00 (+0.00%)6M

Stock Performance

₹1,602.9₹1,585
₹1,609.3
Previous CloseToday's Open
₹1,057₹1,917.8
₹1,609.3
52W Low52W High
₹1,585Today's Open
₹1,602.9Previous Close
1,78,590Volume
₹1,05752W Low
₹1,917.852W High

Ratios

No data available

About Company

  • Onesource Specialty Pharma Limited was initially incorporated as a Private Limited Company, as Inbiopro Solutions Private Limited' dated June 12, 2007, with the Registrar of Companies, Karnataka at Bangalore
  • The name was then changed to Stelis Biopharma Private Limited', pursuant to a Scheme of Amalgamation and a Certificate of Incorporation dated December 24, 2014, was issued by the Registrar of Companies
  • The status of the Company converted into a Public Limited Company, and renamed as Stelis Biopharma Limited' dated July 31, 2021 and subsequently, it changed to Onesource Specialty Pharma Limited' on February 13, 2024
  • In FY 2024-25, a Scheme of Arrangement amongst Strides Pharma Science Limited, Steriscience Specialties Private Limited and the Company and their respective shareholders and creditors was implemented on November 14, 2024
  • Prior to the Scheme of Arrangement, Strides Pharma Science Limited, Steriscience Specialties Private Limited were involved in the businesses of biologics and DDC, soft gelatin capsule and injectables business, respectively
  • Pursuant to the Scheme, Strides Pharma Science Limited, Steriscience Specialties Private Limited got transferred / demerged to and vested with the Company as a going concern effective on April 1, 2024 and the Scheme was made effective from November 27, 2024 with the Registrar of Companies
  • In accordance with the Scheme of Arrangement, 11,44,36,021 Equity Shares of Re
  • 1/- each have been allotted and issued
  • At present, Company is engaged in the research, development, manufacture and commercialisation of biological drug products in various injectable formats
  • It also offers end-to-end Contract Development and Manufacturing Operations (CDMO) services across all phases of pre-clinical and clinical development and commercial supply of biologics

Research Calls

Research Calls
Locked Access

Explore all active research calls & maximize your profits

To access, login or signup with ArihantPlus

Technical Indicators

RSI58.02
SMA 201582.19
SMA 501539.60
SMA 1001569.38
SMA 2001556.02
SMA 101605.43
MACD_12_26_Days25.62
EMA10Day1595.57
EMA20Day1574.69
EMA50Day1554.92
MACD_12_26_9_Days1.40
EMA100Day1566.50
EMA200Day1587.45

Pivot Points

Volume Analysis

Delivery
Total Volume

Growth Rate

Revenue Growth-1.61%
ROE0.00%
EBITDA Margin22.47%

All figures in ₹ Crores

Indicators20262025202420232022
Revenue
1,421.59
1,444.85
171.92
38.71
132.13
Interest
122.19
166.32
89.45
47.55
68.03
Expenses
1,117.37
978.34
260.16
199.40
228.79
Financing Profit
319.24
483.99
-84.01
-157.99
-92.89
Financing Margin %
22%
33%
-49%
-408%
-70%
Other Income
15.02
17.47
4.23
2.69
3.77
Depreciation
279.09
273.88
76.29
65.68
70.35
Profit before tax
-91.96
-67.07
-365.70
-415.65
-231.27
Tax %
20%
74%
0%
0%
0%
Net Profit
-73.80
-17.28
-365.70
-415.65
-231.16
EPS in Rs
-6.44
-1.63
-94.15
-200.87
-65.25
Show % Change
ShareHolding
📊

No Information Available

No shareholding data available at this time.

DealDateTypeQuantityPriceTraded %
KARUNA BUSINESS SOLUTIONS LLP17 Nov ‘25Purchase2,00,000₹1,73527.20%
AMANSA HOLDING PRIVATE LTD.17 Nov ‘25Sell2,00,000₹1,73527.20%

News

📊

No Information Available

No news available for this company.
Record Date
Corporate Action
Information
Announcement Day
23 Sept 2026
AGM
AGM
29 Aug 2026
22 Sept 2025
AGM
AGM
29 Aug 2025

Peers

LTP(₹)
Market Cap(₹ Cr.)
P/E Ratio(Ratio)
P/B Ratio(Ratio)
Cash Earnings(Ratio)
Debt to Equity(Ratio)
Net Profit Ratio(%)
1,614
18,510
0
3
62
0
-4.50%
1,885
4,52,299
37
5
30
0
19.78%
11,200
2,97,325
87
17
76
0
24.32%
4,699
1,78,727
82
10
44
1
11.09%
2,295
1,24,002
93
20
68
1
13.06%
1,195
1,19,207
26
4
18
0
9.82%
1,391
1,16,145
41
3
24
0
12.34%
1,415
1,14,312
37
3
26
0
9.92%
2,660
1,09,870
47
6
34
0
13.57%
1,795
1,03,298
25
3
17
0
10.41%
Showing 10 of 140 Results

Frequently Asked Questions

What is Share Price of OneSource Specialty Pharma Ltd?

The current share price of OneSource Specialty Pharma Ltd (OneSource Speci.) is ₹1609.30. This price reflects the latest market valuation and is updated in real-time during trading hours.

What is the P/E Ratio of OneSource Specialty Pharma Ltd?

The Price-to-Earnings (P/E) ratio of OneSource Specialty Pharma Ltd is 1606.64. This indicates how much investors are willing to pay per rupee of earnings, helping assess if the stock is overvalued or undervalued.

What is the 52-week high and low of OneSource Specialty Pharma Ltd?

OneSource Specialty Pharma Ltd has a 52-week high of ₹1917.80 and a 52-week low of ₹1057.00. This range shows the stock's price volatility over the past year.

What is the Dividend Yield of OneSource Specialty Pharma Ltd?

OneSource Specialty Pharma Ltd offers a dividend yield of 0.00%. This represents the annual dividend payment as a percentage of the current stock price, indicating the income return for investors.

What is the EPS of OneSource Specialty Pharma Ltd?

The Earnings Per Share (EPS) of OneSource Specialty Pharma Ltd is ₹1.00. EPS indicates the company's profitability on a per-share basis and is a key metric for evaluating financial performance.

What is the ROE of OneSource Specialty Pharma Ltd?

OneSource Specialty Pharma Ltd has a Return on Equity (ROE) of 0.34%. ROE measures how effectively the company uses shareholders' equity to generate profits, with higher values generally indicating better performance.

Disclaimer:

Please note that the above list and information is for research purposes only and are not recommendations. Do your own due diligence or consult an investment advisor before investing. The above data is dynamic in nature and subject to real-time changes and is derived from CMOTS.

mobile

Ready to invest smarter?
Download the app today.

GET IT ON

GET IT ON

Google Play

4.5

DOWNLOAD ON THE

DOWNLOAD ON THE

App Store

4.2